Lippert, Undine

[["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","Vaccines"],["dc.bibliographiccitation.volume","10"],["dc.contributor.affiliation","Wellmann, Phoebe; 1Department of Dermatology, University Medical Center Göttingen, 37075 Göttingen, Germany; phoebe.wellmann@stud.uni-goettingen.de (P.W.); christian.kromer@med.uni-goettingen.de (C.K.); johannes.mohr@med.uni-goettingen.de (J.M.); undine.lippert@med.uni-goettingen.de (U.L.)"],["dc.contributor.affiliation","Kromer, Christian; 1Department of Dermatology, University Medical Center Göttingen, 37075 Göttingen, Germany; phoebe.wellmann@stud.uni-goettingen.de (P.W.); christian.kromer@med.uni-goettingen.de (C.K.); johannes.mohr@med.uni-goettingen.de (J.M.); undine.lippert@med.uni-goettingen.de (U.L.)"],["dc.contributor.affiliation","Siemer, Ralf; 2Faculty of Mathematics and Computer Science, University of Göttingen, 37073 Göttingen, Germany; ralf.siemer@stud.uni-goettingen.de"],["dc.contributor.affiliation","Klein, Selina; 3Department of Dermatology and Allergy, University Bonn, 53127 Bonn, Germany; selina.klein@ukbonn.de (S.K.); dagmar.wilsmann-theis@ukbonn.de (D.W.-T.)"],["dc.contributor.affiliation","Mohr, Johannes; 1Department of Dermatology, University Medical Center Göttingen, 37075 Göttingen, Germany; phoebe.wellmann@stud.uni-goettingen.de (P.W.); christian.kromer@med.uni-goettingen.de (C.K.); johannes.mohr@med.uni-goettingen.de (J.M.); undine.lippert@med.uni-goettingen.de (U.L.)"],["dc.contributor.affiliation","Lippert, Undine; 1Department of Dermatology, University Medical Center Göttingen, 37075 Göttingen, Germany; phoebe.wellmann@stud.uni-goettingen.de (P.W.); christian.kromer@med.uni-goettingen.de (C.K.); johannes.mohr@med.uni-goettingen.de (J.M.); undine.lippert@med.uni-goettingen.de (U.L.)"],["dc.contributor.affiliation","Pinter, Andreas; 4Department of Dermatology, Venerology and Allergology, University of Frankfurt, 60590 Frankfurt am Main, Germany; andreas.pinter@kgu.de"],["dc.contributor.affiliation","Wilsmann-Theis, Dagmar; 3Department of Dermatology and Allergy, University Bonn, 53127 Bonn, Germany; selina.klein@ukbonn.de (S.K.); dagmar.wilsmann-theis@ukbonn.de (D.W.-T.)"],["dc.contributor.affiliation","Mössner, Rotraut; 1Department of Dermatology, University Medical Center Göttingen, 37075 Göttingen, Germany; phoebe.wellmann@stud.uni-goettingen.de (P.W.); christian.kromer@med.uni-goettingen.de (C.K.); johannes.mohr@med.uni-goettingen.de (J.M.); undine.lippert@med.uni-goettingen.de (U.L.)"],["dc.contributor.author","Wellmann, Phoebe"],["dc.contributor.author","Kromer, Christian"],["dc.contributor.author","Siemer, Ralf"],["dc.contributor.author","Klein, Selina"],["dc.contributor.author","Mohr, Johannes"],["dc.contributor.author","Lippert, Undine"],["dc.contributor.author","Pinter, Andreas"],["dc.contributor.author","Wilsmann-Theis, Dagmar"],["dc.contributor.author","Mössner, Rotraut"],["dc.date.accessioned","2022-07-11T06:54:31Z"],["dc.date.available","2022-07-11T06:54:31Z"],["dc.date.issued","2022-06-23"],["dc.date.updated","2022-07-08T13:34:06Z"],["dc.description.abstract","While suboptimal pneumococcal vaccination rates have been reported in immunosuppressed patients with rheumatic diseases, data for patients with psoriasis (PsO) or atopic dermatitis (AD) are scarce. Pneumococcal vaccination in Germany is recommended in patients with certain comorbidities, immunosuppression, and/or aged 60 years or above. The aim of this multicenter cross-sectional study was to investigate the pneumococcal vaccination rate in patients with PsO compared to patients with AD and to evaluate patient perceptions. All patients completed a questionnaire on vaccination status and perceptions, patient and disease characteristics, as well as comorbidity. Medical records and vaccination certificates were reviewed. Over the whole cohort (n = 327 PsO (41.9% female), n = 98 AD (42.9% female)), 83.8% and 42.9% of PsO and AD patients, respectively, had an indication for pneumococcal vaccination due to immunosuppressive treatment. The pneumococcal vaccination rate was 14.4% and 10.2% in PsO and AD patients, respectively. The vaccination rate depended significantly on age, working status and presence of psoriatic arthritis. The most common reason for nonvaccination was lacking recommendation by physicians. Higher awareness, particularly for vaccination indication due to immunosuppression among dermatologists, general physicians, and patients, is warranted."],["dc.description.sponsorship","Novartis Pharma"],["dc.identifier.doi","10.3390/vaccines10071005"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/112431"],["dc.language.iso","en"],["dc.relation.eissn","2076-393X"],["dc.rights","CC BY 4.0"],["dc.title","Low Pneumococcal Vaccination among Patients with Psoriasis in Germany: Results from Vac-Pso"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1063"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Pediatric Dermatology"],["dc.bibliographiccitation.lastpage","1067"],["dc.bibliographiccitation.volume","37"],["dc.contributor.author","Ferrari, David M."],["dc.contributor.author","Hoffmann, Johanna C."],["dc.contributor.author","Schön, Michael P."],["dc.contributor.author","Lippert, Undine"],["dc.date.accessioned","2021-04-14T08:32:54Z"],["dc.date.available","2021-04-14T08:32:54Z"],["dc.date.issued","2020"],["dc.description.abstract","Abstract Background/Objectives Para‐phenylenediamine, a dye frequently added to henna tattoos to create the black color, is a potent contact allergen. Severe contact dermatitis may arise within days even after the first application. Our objective was to develop a method for rapid and complete removal of para‐phenylenediamine‐containing black henna tattoos from the skin, an important problem many physicians are confronted with, but for which no simple method exists. Methods A database search revealed polyethylene glycol 400, described in removal of ortho‐phenylenediamine from contaminated skin. We therefore investigated its use in removal of the structurally related ortholog para‐phenylenediamine present in black henna tattoos. Results A protocol was established involving repeated cycles of rinsing of the skin with polyethylene glycol 400 solution. In 5 patients, one of whom had already developed a severe blistering contact dermatitis and another a mild erosive dermatitis, black henna tattoos were successfully removed. Removal was completed in a single session of 1 hour or less, depending on tattoo size, with a maximum of 6 rinse cycles. Conclusions We provide a simple and safe method for rapid and effective removal of black henna tattoos. This procedure requires no special equipment and can be applied in virtually any setting."],["dc.identifier.doi","10.1111/pde.14349"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/84051"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.relation.eissn","1525-1470"],["dc.relation.issn","0736-8046"],["dc.rights","This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made."],["dc.title","Efficient removal of black henna tattoos"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]